Business Wire

Tommy Hilfiger Accelerates Sustainability Journey With Ambitious Make it Possible Program

Share

Tommy Hilfiger, which is owned by PVH Corp. [NYSE:PVH] announces Make it Possible, a bold approach to environmental and social sustainability that reinforces the organization’s commitment to create fashion that ‘Wastes Nothing and Welcomes All’. With Make it Possible, Tommy Hilfiger is initially committing to 24 ambitious targets centered around circularity and inclusivity, outlined across four pillars towards 2030:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200830005002/en/

  • Circle Round: Make products to be fully circular, and part of a sustainable loop.
  • Made for Life: Operate with sensitivity to planetary boundaries, for instance in the areas of climate change, land use, freshwater and chemical pollution, from what we buy to where we sell.
  • Everyone Welcome: Be a brand that works for every TOMMY Fan – always inclusive, completely accessible.
  • Opportunity for All: Create equal access to opportunity – no barriers to success at Tommy Hilfiger.

Tommy Hilfiger’s program is powered by parent company PVH Corp’s Forward Fashion strategy, a set of 15 priorities designed to reduce negative impacts to zero, increase positive impacts to 100%, and improve the over 1 million lives across the company’s value chain.

“I opened my first store, People’s Place, in 1969 in my hometown of Elmira for people of all backgrounds to come together and share exciting pop culture experiences,” said Tommy Hilfiger. “As our brand has evolved over the years, driven by this inclusive spirit, so has our commitment to social and environmental sustainability. With Make it Possible, we will go even further with our commitment. We’re working towards our vision with the entire organization focused on it and, while we’re not there yet, we are going to get there.”

“In these times of health, human, environmental and economic crisis, we share a responsibility to find innovative solutions that will encourage inclusivity and build a more circular future,” said Martijn Hagman, CEO, Tommy Hilfiger Global and PVH Europe. “It is in our nature to drive change, even in the most challenging of times, which is why we are announcing our ambitious Make it Possible sustainability program, outlining 24 targets towards 2030. Tommy Hilfiger has a decade’s long track-record for driving a more sustainable future, including pioneering low impact denim processes, championing water stewardship, and creating more inclusive collections. Make it Possible is one way we will work together to make a meaningful and lasting contribution towards a better fashion industry.”

Make it Possible marks the latest milestone in Tommy Hilfiger’s sustainability journey. Key achievements include the launch of Tommy Hilfiger Adaptive, designed to make dressing easier for adults and children with disabilities, and the Tommy Hilfiger Fashion Frontier Challenge, a global program aimed to support start-up and scale-up stage businesses developing solutions that promote inclusivity and sustainability in fashion. More recently Tommy Hilfiger launched People’s Place Program to advance the representation of black, indigenous and people of color (BIPOC) communities within the fashion and creative industries. To date, more than 80% of Tommy Hilfiger designers have been trained on circular design strategies and, in 2019, 72% of cotton used globally came from more sustainable sources. Additionally 2 million pieces of denim have been finished in lower impact, reducing the amount of water and energy used. Each seasonal TOMMY HILFIGER collection includes more sustainable styles in its collections, as evidenced by the 50% more sustainable styles planned for Spring 2021, double the amount from Spring 2020.

Recognizing that no one company can change the sustainability landscape alone, Tommy Hilfiger, as part of PVH Corp., has joined forces with industry partners by signing The Fashion Pact in August 2019, as well as joining the Ellen MacArthur Foundation Make Fashion Circular and Jeans Redesign initiatives. For the past several years, Tommy Hilfiger has partnered with the WWF to address water risk in our strategic supply chain locations. This includes training on water risk management for suppliers and industrial parks in China’s Taihu River Basin and serving as the founding brand partner of a new water stewardship program in Vietnam in the Mekong basin.

Throughout its journey, Tommy Hilfiger will share its progress. For more information on Make it Possible and a full overview of achievements to date, visit: http://sustainability.tommy.com.

About Tommy Hilfiger
With a brand portfolio that includes TOMMY HILFIGER and TOMMY JEANS, Tommy Hilfiger is one of the world’s most recognized premium designer lifestyle groups. Its focus is designing and marketing high-quality men’s tailored clothing and sportswear, women’s collection apparel and sportswear, kidswear, denim collections, underwear (including robes, sleepwear and loungewear), footwear and accessories. Through select licensees, Tommy Hilfiger offers complementary lifestyle products such as eyewear, watches, fragrance, swimwear, socks, small leather goods, home goods and luggage. The TOMMY JEANS product line consists of jeanswear and footwear for men and women, accessories, and fragrance. Merchandise under the TOMMY HILFIGER and TOMMY JEANS brands is available to consumers worldwide through an extensive network of TOMMY HILFIGER and TOMMY JEANS retail stores, leading specialty and department stores, select online retailers, and at tommy .com.

About PVH Corp.
PVH is one of the most admired fashion and lifestyle companies in the world. We power brands that drive fashion forward – for good. Our brand portfolio includes the iconic CALVIN KLEIN , TOMMY HILFIGER, Van Heusen, IZOD, ARROW, Warner’s, Olga and Geoffrey Beene brands, as well as the digital-centric True&Co. intimates brand. We market a variety of goods under these and other nationally and internationally known owned and licensed brands. PVH has over 40,000 associates operating in over 40 countries and $9.9 billion in annual revenues. That's the Power of Us. That’s the Power of PVH.

Follow us on Facebook , Instagram, Twitter and LinkedIn.

Contact information

Tommy Hilfiger
Baptiste Blanc
Sr. Director, Communications and Earned Media
Baptiste.Blanc@tommy.com
+31 62904 2334

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 19:30:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom